Half-year report · HY
9627.TEDINET S100XAGJ
Period2025-05-01 → 2025-10-31
Filed2025-12-15
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥299.9bn | 2025-05-01 → 2025-10-31 | Cons. | Net sales |
| Revenue | ¥456.8bn | 2024-05-01 → 2025-04-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥214.9bn | 2024-05-01 → 2024-10-31 | Cons. | Net sales |
| Operating income | ¥10.5bn | 2025-05-01 → 2025-10-31 | Cons. | Operating income |
| Operating income | ¥5.9bn | 2024-05-01 → 2024-10-31 | Cons. | Operating income |
| Ordinary income | ¥9.9bn | 2025-05-01 → 2025-10-31 | Cons. | Ordinary income |
| Ordinary income | ¥18.1bn | 2024-05-01 → 2025-04-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.3bn | 2024-05-01 → 2024-10-31 | Cons. | Ordinary income |
| Profit before tax | ¥9.6bn | 2025-05-01 → 2025-10-31 | Cons. | Income before income taxes |
| Profit before tax | ¥6.7bn | 2024-05-01 → 2024-10-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥4.5bn | 2025-05-01 → 2025-10-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥9.3bn | 2024-05-01 → 2025-04-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.2bn | 2024-05-01 → 2024-10-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥4.5bn | 2025-05-01 → 2025-10-31 | Cons. | Profit loss |
| Net income | ¥3.2bn | 2024-05-01 → 2024-10-31 | Cons. | Profit loss |
| Total assets | ¥514.6bn | at 2025-10-31 | Cons. | Assets |
| Total assets | ¥311.9bn | at 2025-04-30 | Cons. | Assets |
| Total assets | ¥296.0bn | at 2024-10-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥369.1bn | at 2025-10-31 | Cons. | Liabilities |
| Total liabilities | ¥169.3bn | at 2025-04-30 | Cons. | Liabilities |
| Net assets / equity | ¥145.5bn | at 2025-10-31 | Cons. | Net assets |
| Net assets / equity | ¥142.6bn | at 2025-04-30 | Cons. | Net assets |
| Net assets / equity | ¥136.1bn | at 2024-10-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥53.1bn | at 2025-10-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥26.9bn | at 2025-04-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥52.8bn | at 2025-10-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.7bn | at 2025-04-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥27.2bn | at 2024-10-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥48.4bn | at 2024-04-30v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.2bn | 2025-05-01 → 2025-10-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥23.1bn | 2024-05-01 → 2025-04-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥12.7bn | 2024-05-01 → 2024-10-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥53.2bn | 2025-05-01 → 2025-10-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥65.9bn | 2024-05-01 → 2025-04-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥54.0bn | 2024-05-01 → 2024-10-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥78.2bn | 2025-05-01 → 2025-10-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥21.1bn | 2024-05-01 → 2025-04-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥20.1bn | 2024-05-01 → 2024-10-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥128.05 | 2025-05-01 → 2025-10-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥264.32 | 2024-05-01 → 2025-04-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥91.75 | 2024-05-01 → 2024-10-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 28.2% | at 2025-10-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.7% | at 2025-04-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.0% | at 2024-10-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 34
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2025-05-01 → 2025-10-31 | ¥5.7bn |
| Otherother segments | revenue external | 2025-05-01 → 2025-10-31 | ¥5.5bn |
| Otherother segments | revenue intersegment | 2025-05-01 → 2025-10-31 | ¥134m |
| Otherother segments | segment ordinary income | 2025-05-01 → 2025-10-31 | ¥14m |
| Reconciling Itemsreconciling | revenue | 2025-05-01 → 2025-10-31 | −¥134m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-05-01 → 2025-10-31 | −¥134m |
| Reconciling Itemsreconciling | segment ordinary income | 2025-05-01 → 2025-10-31 | −¥6.5bn |
| Dispensing Pharmacyreportable segment | revenue | 2025-05-01 → 2025-10-31 | ¥254.7bn |
| Dispensing Pharmacyreportable segment | revenue external | 2025-05-01 → 2025-10-31 | ¥254.7bn |
| Dispensing Pharmacyreportable segment | segment ordinary income | 2025-05-01 → 2025-10-31 | ¥12.8bn |
| Drug And Cosmetic Storereportable segment | revenue | 2025-05-01 → 2025-10-31 | ¥39.6bn |
| Drug And Cosmetic Storereportable segment | revenue external | 2025-05-01 → 2025-10-31 | ¥39.6bn |
| Drug And Cosmetic Storereportable segment | segment ordinary income | 2025-05-01 → 2025-10-31 | ¥3.5bn |
| —segment total | revenue | 2025-05-01 → 2025-10-31 | ¥300.0bn |
| —segment total | revenue external | 2025-05-01 → 2025-10-31 | ¥299.9bn |
| —segment total | revenue intersegment | 2025-05-01 → 2025-10-31 | ¥134m |
| —segment total | segment ordinary income | 2025-05-01 → 2025-10-31 | ¥16.4bn |
| Otherother segments | revenue | 2024-05-01 → 2024-10-31 | ¥5.6bn |
| Otherother segments | revenue external | 2024-05-01 → 2024-10-31 | ¥5.5bn |
| Otherother segments | revenue intersegment | 2024-05-01 → 2024-10-31 | ¥24m |
| Otherother segments | segment ordinary income | 2024-05-01 → 2024-10-31 | −¥15m |
| Reconciling Itemsreconciling | revenue | 2024-05-01 → 2024-10-31 | −¥24m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-05-01 → 2024-10-31 | −¥24m |
| Reconciling Itemsreconciling | segment ordinary income | 2024-05-01 → 2024-10-31 | −¥5.0bn |
| Dispensing Pharmacyreportable segment | revenue | 2024-05-01 → 2024-10-31 | ¥186.4bn |
| Dispensing Pharmacyreportable segment | revenue external | 2024-05-01 → 2024-10-31 | ¥186.4bn |
| Dispensing Pharmacyreportable segment | segment ordinary income | 2024-05-01 → 2024-10-31 | ¥9.6bn |
| Drug And Cosmetic Storereportable segment | revenue | 2024-05-01 → 2024-10-31 | ¥22.9bn |
| Drug And Cosmetic Storereportable segment | revenue external | 2024-05-01 → 2024-10-31 | ¥22.9bn |
| Drug And Cosmetic Storereportable segment | segment ordinary income | 2024-05-01 → 2024-10-31 | ¥1.7bn |
| —segment total | revenue | 2024-05-01 → 2024-10-31 | ¥214.9bn |
| —segment total | revenue external | 2024-05-01 → 2024-10-31 | ¥214.9bn |
| —segment total | revenue intersegment | 2024-05-01 → 2024-10-31 | ¥24m |
| —segment total | segment ordinary income | 2024-05-01 → 2024-10-31 | ¥11.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 581
| Item | Context | Value | Unit |
|---|---|---|---|
| Selling general and administrative expenses | Prior1InterimDuration | 24224000000 | JPY |
| Selling general and administrative expenses | InterimDuration | 37874000000 | JPY |
| Operating income | Prior1InterimDuration | 5872000000 | JPY |
| Operating income | InterimDuration | 10517000000 | JPY |
| Interest income noi | Prior1InterimDuration | 12000000 | JPY |
| Interest income noi | InterimDuration | 65000000 | JPY |
| Dividends income noi | Prior1InterimDuration | 22000000 | JPY |
| Dividends income noi | InterimDuration | 31000000 | JPY |
| Commission fee noi | Prior1InterimDuration | 3000000 | JPY |
| Commission fee noi | InterimDuration | 4000000 | JPY |
| Real estate rent noi | Prior1InterimDuration | 153000000 | JPY |
| Real estate rent noi | InterimDuration | 159000000 | JPY |
| Fiduciary obligation fee noi | Prior1InterimDuration | 179000000 | JPY |
| Fiduciary obligation fee noi | InterimDuration | 240000000 | JPY |
| Subsidy income noi | Prior1InterimDuration | 74000000 | JPY |
| Subsidy income noi | InterimDuration | 98000000 | JPY |
| Other noi | Prior1InterimDuration | 313000000 | JPY |
| Other noi | InterimDuration | 345000000 | JPY |
| Non operating income | Prior1InterimDuration | 760000000 | JPY |
| Non operating income | InterimDuration | 943000000 | JPY |
| Interest expenses noe | Prior1InterimDuration | 84000000 | JPY |
| Interest expenses noe | InterimDuration | 882000000 | JPY |
| Loss on transfer of receivables noe | Prior1InterimDuration | 123000000 | JPY |
| Loss on transfer of receivables noe | InterimDuration | 268000000 | JPY |
| Rent expenses on real estates noe | Prior1InterimDuration | 46000000 | JPY |
| Rent expenses on real estates noe | InterimDuration | 334000000 | JPY |
| Other noe | Prior1InterimDuration | 38000000 | JPY |
| Other noe | InterimDuration | 63000000 | JPY |
| Non operating expenses | Prior1InterimDuration | 293000000 | JPY |
| Non operating expenses | InterimDuration | 1547000000 | JPY |
| Ordinary income | Prior1InterimDuration | 6338000000 | JPY |
| Ordinary income | InterimDuration | 9913000000 | JPY |
| Gain on sales of noncurrent assets ei | Prior1InterimDuration | 3000000 | JPY |
| Gain on sales of noncurrent assets ei | InterimDuration | 0 | JPY |
| Gain on sales of investment securities ei | Prior1InterimDuration | 18000000 | JPY |
| Gain on sales of investment securities ei | InterimDuration | 27000000 | JPY |
| Gain on transfer of business ei | Prior1InterimDuration | 527000000 | JPY |
| Gain on transfer of business ei | InterimDuration | 48000000 | JPY |
| Other ei | Prior1InterimDuration | 0 | JPY |
| Other ei | InterimDuration | 3000000 | JPY |
| Extraordinary income | Prior1InterimDuration | 550000000 | JPY |
| Extraordinary income | InterimDuration | 80000000 | JPY |
| Loss on sales and retirement of noncurrent assets el | Prior1InterimDuration | 38000000 | JPY |
| Loss on sales and retirement of noncurrent assets el | InterimDuration | 243000000 | JPY |
| Impairment loss el | Prior1InterimDuration | 72000000 | JPY |
| Impairment loss el | InterimDuration | 62000000 | JPY |
| Loss on valuation of investment securities el | Prior1InterimDuration | 43000000 | JPY |
| Loss on valuation of investment securities el | InterimDuration | 16000000 | JPY |
| Other el | Prior1InterimDuration | 5000000 | JPY |
| Other el | InterimDuration | 58000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |